Maximilian Papi
Overview
Explore the profile of Maximilian Papi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
324
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cappuzzo F, Ricciuti B, Delmonte A, Bonanno L, Wang X, Lye W, et al.
Clin Cancer Res
. 2025 Jan;
PMID: 39836372
Background: The role of activating alterations in the MAPK pathway in predicting immunotherapy efficacy in lung squamous cell carcinoma (LSCC) patients is largely unknown. The aims of the randomized, phase...
2.
Canale M, Petracci E, Delmonte A, Bronte G, Chiadini E, Ludovini V, et al.
J Clin Med
. 2020 Apr;
9(4).
PMID: 32272775
Background: Non-small cell lung cancer (NSCLC) is the primary cause of cancer-related deaths worldwide. Epidermal Growth Factor Receptor ()-mutated patients usually benefit from TKIs treatment, but a significant portion show...
3.
Santo A, Pilotto S, Galetta D, Grossi F, Fasola G, Romano G, et al.
Lung Cancer
. 2019 Jul;
134:121-126.
PMID: 31319970
Objectives: Considering the frequent expression of somatostatine receptors, we designed the G04.2011 trial to investigate the efficacy of the somatostatine analogue lanreotide in maintenance for SCLC patients after response to...
4.
Chiadini E, Canale M, Delmonte A, Dazzi C, Casanova C, Capelli L, et al.
J Thorac Dis
. 2018 Sep;
10(8):4858-4864.
PMID: 30233859
Background: Molecular diagnostics for non-small cell lung cancer (NSCLC) has become the standard of care for personalized treatment. Epidermal growth factor receptor () mutation and translocation represent the two most...
5.
Tassinari D, Cherubini C, Tamburini E, Drudi F, Papi M, Fantini M, et al.
J Chemother
. 2017 Jul;
29(6):365-371.
PMID: 28697647
An indirect comparison of cisplatin-pemetrexed (CP) and cisplatin-raltitrexed (CR) was performed. The Odds Ratios of 10, 15 and 20 month survival rate and response rate were assumed as indexes of...
6.
Canale M, Petracci E, Delmonte A, Chiadini E, Dazzi C, Papi M, et al.
Clin Cancer Res
. 2016 Nov;
23(9):2195-2202.
PMID: 27780855
To analyze the impact of mutations on response to first-line tyrosine kinase inhibitors (TKI) in patients with -mutated non-small cell lung cancer (NSCLC). 136 -mutated NSCLC patients receiving first-line TKIs...
7.
Ulivi P, Chiadini E, Dazzi C, Dubini A, Costantini M, Medri L, et al.
Clin Lung Cancer
. 2015 Dec;
17(5):384-390.
PMID: 26712101
Background: Epidermal growth factor receptor (EGFR) and v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations, and echinoderm microtubule-associated protein-like 4 (EML4) anaplastic lymphoma kinase (ALK) translocation are generally considered...
8.
Ulivi P, Delmonte A, Chiadini E, Calistri D, Papi M, Mariotti M, et al.
Int J Mol Sci
. 2015 Jan;
16(1):747-57.
PMID: 25561229
Tyrosine kinase inhibitors (TKIs) are very efficacious in non-small-cell lung cancer (NSCLC) patients harboring activating Epidermal Growth Factor Receptor (EGFR) mutations. However, about 10% of EGFR wild type (wt) patients...
9.
Dazzi C, Cariello A, Casanova C, Verlicchi A, Montanari M, Papiani G, et al.
Clin Lung Cancer
. 2012 Apr;
14(1):28-33.
PMID: 22537509
Background: Although small-cell lung cancer is a chemosensitive malignancy, most patients rapidly relapse. Results of second-line treatment are generally poor. We conducted a phase II study to evaluate the activity...
10.
Tassinari D, Sartori S, Papi M, Drudi F, Castellani C, Carloni F, et al.
Oncology
. 2011 Jul;
80(5-6):350-8.
PMID: 21791945
Background: To assess the efficacy and safety of bevacizumab-containing regimens in the treatment of advanced, chemotherapy-naive, non-squamous non-small cell lung cancer (NSCLC) on the basis of the two registrative trials...